Nymox Pharma (NYMX) Reports Encouraging Data from NX-1207 Phase 2
Tweet Send to a Friend
Nymox Pharmaceutical Corp (Nasdaq: NYMX) reports that the Independent Data Monitoring Committee for the Company's Phase 2 study of NX-1207 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
